Co-receptor usage and prediction of V3 genotyping algorithms in HIV-1 subtype B' from paid blood donors experienced anti-retroviral therapy in Chinese central province.
Co-receptor usage and prediction of V3 genotyping algorithms in HIV-1 subtype B' from paid blood donors experienced anti-retroviral therapy in Chinese central province.
复制标题
DOI：
10.1186/1743-422x-7-280
复制
发表时间：
2010-10-22
期刊：
影响因子：
4.8
通讯作者：
Shao Y
中科院分区：
文献类型：
--
作者：
Qu S;Ma L;Yuan L;Xu W;Hong K;Xing H;Huang Y;Yu X;Shao Y
本研究旨在探讨中国中部省份HIV-1 B'亚型有偿献血者抗逆转录病毒治疗后V3基因分型算法的辅助受体使用和预测，以设计有效的治疗方案。在治疗HIV-1感染和未经治疗的HIV-1感染中分离HIV-1毒株，然后使用流式细胞术基于Ghost细胞系鉴定HIV-1毒株的共受体使用。将HIV-1 V3区扩增并提交到网络服务器（WebPSSM和geno 2 pheno）中以预测HIV-1共受体的使用。通过比较V3基因分型预测算法和基于Ghost细胞系的HIV表型检测方法，分析了Web服务器检测方法预测HIV-1使用量的可行性。从接受抗逆转录病毒治疗的HIV-1感染者和未接受过抗逆转录病毒治疗的HIV-1感染者中分别分离出45株和114株HIV-1。41%来自ART患者的临床病毒和18%来自初治患者的临床病毒使用CXCR 4作为共受体。V3环的净电荷在两组中有显著差异。11/25规则预测共受体容量的敏感性和特异性分别为54.6%和90.0%，Web-PSSMx 4 r5预测共受体容量的敏感性和特异性分别为50.0%和90%，Geno 2 pheno预测共受体容量的敏感性和特异性分别为68.2%和40.0%。双重/混合/X4共受体利用率在ART患者中高于初治患者。基于V3基因分型算法的HIV-1 B'亚型共受体使用预测值得关注。
This study explored co-receptor usage and prediction of V3 genotyping algorithms in HIV-1 subtype B' from paid blood donors experienced anti-retroviral therapy in Chinese central province in order to design effectively therapeutic regimen. HIV-1 strains were isolated in treatment HIV-1 infections and treatment-naïve HIV-1 infections, then co-receptor usage of HIV-1 strains was identified based on Ghost cell lines using flow cytometry. HIV-1 V3 region was amplified and submitted into web-server (WebPSSM and geno2pheno) to predict HIV-1 co-receptor usage. The feasibility of prediction HIV-1 usage with Web-server assay was analyzed by comparing prediction of V3 genotyping algorithms with HIV phenotype assay based on Ghost cell line. 45 HIV-1 strains and 114 HIV-1 strains were isolated from HIV-1 infections exposed anti-retroviral therapy and treatment-naïve, respectively. 41% clinical viruses from ART patients and 18% from treatment-naïve patients used CXCR4 as co-receptor. The net charge in the V3 loop was significantly difference in both groups. The sensitivity and specificity for predicting co-receptor capacity is 54.6% and 90.0% on 11/25 rule, 50.0% and 90% on Web-PSSMx4r5, 68.2% and 40.0% on Geno2pheno[co-receptor]. Dual/mixed/X4 co-receptor utilization was higher in ART patients than treatment-naïve patients. It is should paid attention to predicting HIV-1 co-receptor usage based on V3 genotyping algorithms in HIV-1 subtype B' from paid blood donors experienced anti-retroviral therapy in Chinese central province.